EUVIMEDEUVIMED entdecken
Crossref

Risk of Major Congenital Malformations Associated With First‐Trimester Exposure to Topical Antifungal Medications: A Large Claims Database Study

Tadaharu Kunitoki, Takamasa Sakai iD, Tomofumi Ishikawa, Ryo Obara iD, Kei Morishita iD, Azusa Hara, Motohiko Adomi, Haruto Watanabe, Kaya Hayasaka, Yuna Yoshida, Aki Shimizu, Genki Shinoda und 10 weitere

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Tadaharu Kunitoki und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan. Hauptthemen laut MEDLINE: Antifungal Agents, Abnormalities, Drug-Induced, Candidiasis, Vulvovaginal, Pregnancy Complications, Infectious. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Ministry of Health, Labour and Welfare of Japan, Japan Society for the Promotion of Science KAKENHI, Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Vulvovaginal candidiasis is highly prevalent among pregnant women, and its treatment is crucial. However, there is a lack of evidence regarding the risks on fetal outcomes associated with the use of antifungal medications during the first trimester of pregnancy in Japan. This study examined the association between topical antifungal use during the first trimester of pregnancy and the risk of major congenital malformations (MCMs) in infants using a Japanese database.

Methods

We conducted a cohort study using a pregnancy cohort nested in the JMDC Claims Database from Japan. This dataset included 12 472 women who gave birth between 2010 and 2019 and were diagnosed with vulvovaginal candidiasis. Among the antifungal medications frequently dispensed or prescribed during the first trimester of pregnancy in this cohort, miconazole, oxiconazole, and isoconazole were assessed for the risk of MCMs, using clotrimazole, an antifungal medication with established safety during pregnancy, as a reference.

Results

Among 12 472 women, the overall prevalence of MCMs was 5.8% ( n = 249) in women exposed to topical antifungals, while unexposed were 6.2% ( n = 508). Using propensity score overlap weight (wOR), no increased risk of MCMs in infants was observed in pregnancies exposed to oxiconazole, isoconazole, and miconazole compared to clotrimazole (overlap weighted odds ratio [95% confidence interval]: 0.875 [0.599–1.277], 1.001 [0.611–1.640], and 0.887 [0.497–1.581], respectively).

Conclusion

There was no significant association between topical antifungal use during the first trimester of pregnancy and the risk of MCMs in infants in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsAbnormalities, Drug-InducedCandidiasis, VulvovaginalPregnancy Complications, InfectiousHumansFemalePregnancyPregnancy Trimester, FirstJapanAdultDatabases, FactualAdministration, TopicalCohort StudiesInfant, NewbornYoung AdultPrevalence

Stichwörter der Autor:innen

antifungal medicationsdatabasemalformationpregnancy

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Division of Clinical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
  • Drug Informatics, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
  • Laboratory of Biomolecule and Pathophysiological Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
  • Division of Molecular Epidemiology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.
  • Laboratory of Social Pharmacy and Public Health, Showa Pharmaceutical University, Machida, Japan.

ORCID-Profile: Takamasa Sakai, Ryo Obara, Kei Morishita, Aoi Noda

Förderung

  • Ministry of Health, Labour and Welfare of Japan
  • Japan Society for the Promotion of Science KAKENHI
  • Ministry of Health, Labour and Welfare

Zitieren

APA

Kunitoki, T., Sakai, T., Ishikawa, T., Obara, R., Morishita, K., Hara, A., Adomi, M., Watanabe, H., Hayasaka, K., Yoshida, Y., Shimizu, A., Shinoda, G., Noda, A., Ishikuro, M., Orui, M., Iwama, N., Yamakoshi, S., Sato, E., Mano, N., …, & Obara, T. (2025). Risk of Major Congenital Malformations Associated With First‐Trimester Exposure to Topical Antifungal Medications: A Large Claims Database Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70274

Vancouver

Kunitoki T, Sakai T, Ishikawa T, Obara R, Morishita K, Hara A, et al. Risk of Major Congenital Malformations Associated With First‐Trimester Exposure to Topical Antifungal Medications: A Large Claims Database Study. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70274

BibTeX
@article{Kunitoki2025,
  author = {Kunitoki, Tadaharu and Sakai, Takamasa and Ishikawa, Tomofumi and Obara, Ryo and Morishita, Kei and Hara, Azusa and Adomi, Motohiko and Watanabe, Haruto and Hayasaka, Kaya and Yoshida, Yuna and Shimizu, Aki and Shinoda, Genki and Noda, Aoi and Ishikuro, Mami and Orui, Masatsugu and Iwama, Noriyuki and Yamakoshi, Seiko and Sato, Emiko and Mano, Nariyasu and Kuriyama, Shinichi and Takahashi, Nobuyuki and Obara, Taku},
  title = {Risk of Major Congenital Malformations Associated With First‐Trimester Exposure to Topical Antifungal Medications: A Large Claims Database Study},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70274}
}
Kostenlos starten →